George Papandreou - Sep 19, 2023 Form 3 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
Title: General Manager and Senior Vice President, Focal Therapies Exhibit 24 - Power of Attorney
Signature
/s/ Silas Newcomb, Attorney-in-Fact
Stock symbol
OBIO
Transactions as of
Sep 19, 2023
Transactions value $
$0
Form type
3
Date filed
9/29/2023, 09:33 PM
Next filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OBIO Common Stock, par value $0.0001 per share ("Common Stock") 20K Sep 19, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OBIO Stock Option (Right to Buy) Sep 19, 2023 Common Stock 23.3K $4.75 Direct F2
holding OBIO Stock Option (Right to Buy) Sep 19, 2023 Common Stock 6.28K $4.06 Direct F3
holding OBIO Stock Option (Right to Buy) Sep 19, 2023 Common Stock 23.6K $10.00 Direct F4
holding OBIO Stock Option (Right to Buy) Sep 19, 2023 Common Stock 30K $7.77 Direct F5
holding OBIO Warrants (Right to Buy) Sep 19, 2023 Common Stock 50K $11.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of July 24, 2023 (the "Vesting Commencement Date"), (ii) 33% the shares will vest on the two-year anniversary of the Vesting Commencement Date, and (iii) 33% of the shares will vest on the three-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service through such dates.
F2 The stock options vest over a three-year period in equal monthly installments beginning on the one-month anniversary of the grant date, subject to the Reporting Person's continous service through such dates. The grant date was August 5, 2021.
F3 The stock options vest over a three-year period as follows: (i) 33% of the undelrying shares will vest on the one-year anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting on the last day of the first quarter after the first year anniversary of the grant date, subject to the Reporting Person's continous service through such dates. The grant date was April 12, 2022.
F4 The stock options vest over a three-year period as follows: (i) 33% of the undelrying shares will vest on the one-year anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting on the last day of the first quarter after the first year anniversary of the grant date, subject to the Reporting Person's continous service through such dates. The grant date was August 18, 2022.
F5 The stock options vest over a four-year period as follows: (i) 25% of the undelrying shares will vest on the one-year anniversary of the grant date and (ii) 75% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting on the last day of the first quarter after the first year anniversary of the grant date, subject to the Reporting Person's continous service through such dates. The grant date was July 1, 2023.
F6 50% of the shares of Common Stock underlying the Warrants will vest and become exercisable on January 26, 2025, and the remaining 50% of the shares of Common Stock underlying the Warrants will vest and become exercisable on Janaury 26, 2026, in each case subject to the Reporting Person's continuous service through such dates.

Remarks:

Title: General Manager and Senior Vice President, Focal Therapies Exhibit 24 - Power of Attorney